97 results about "Glycemic management" patented technology

The invention discloses a blood glucose management method, a user interface and a related device, and the method can determine a first meal time based on a historical blood glucose value of a user, and determine a second meal time based on one or more of the meal time input by the user, the limb movement of the user and the heart rate. Third meal time is determined based on the first meal time and the second meal time, and the blood glucose health condition of the user is evaluated according to the third meal time. Therefore, according to the method, the dining time of the user can be predicted in combination with the dining time, determined in various modes, of the user in the historical diet event, and the electronic equipment can evaluate the blood glucose condition of the user more accurately.

The invention relates to the technical field of artificial intelligence, and discloses a blood glucose management system based on artificial intelligence. According to the system, blood glucose monitoring is reminded through the blood glucose monitoring terminal, a blood glucose curve is drawn every week, abnormal blood glucose conditions are judged for reminding and alarming, the diet terminal is used for guiding low-sugar diet recommendation, high-sugar food intake is avoided, the mastering degree of a patient and family members for food classification is improved, and the exercise terminal determines the exercise time and exercise amount of the patient according to the blood glucose value. Parameters are input into an intelligent system, the system converts and selects a motion mode, time and intensity, a drug treatment terminal calculates the insulin injection amount of a patient every day and every meal according to the blood glucose level and food intake, the insulin dosage is adjusted according to the calculated numerical values, blood glucose fluctuation is reduced, and the treatment effect is improved. The education and self-management terminal guides a patient to improve the cognitive degree of diabetes and provides personalized propaganda and education guidance for the patient, and the complication reminding terminal controls the blood sugar of the patient within a normal range, guides a good lifestyle of the patient and guides behavior specifications.

The invention relates to the technical field of medical care informatization, in particular to a diabetes and early-stage patient self-management system based on AI and CGM, which comprises the following steps: carrying out delayed alignment on CGM blood glucose flow and multi-modal physiological signals through a signal acquisition and synchronization module; an intelligent event triggering module is used for dynamically adjusting a triggering threshold value for different disease course stages so as to identify suspected events; a mixed consistency verification engine is combined with a medical prior rule and an ensemble classification model to carry out joint discrimination, and a consistency probability is output; and the individual parameters are optimized in cooperation with a hierarchical decision-making mechanism of the interaction module and online incremental learning of the adaptive learning module. Therefore, frequent false alarms caused by physical limitations such as inherent physiological delay and signal drifting of a CGM sensor and alarm fatigue and decline of compliance of a patient caused by the frequent false alarms are solved, and more stable and personalized dynamic blood glucose management support is provided for active people in the early stage of diabetes mellitus and the like.

A blood glucose management method, a user interface, and a related apparatus. The blood glucose management method comprises: on the basis of historical blood glucose levels of a user, determining a first mealtime; on the basis of one or more of a mealtime inputted by the user, and body movements and the heart rate of the user, determining a second mealtime; on the basis of the first mealtime and the second mealtime, determining a third mealtime; and assessing a blood glucose health status of the user by means of the third mealtime. Historical mealtimes of a user that are determined using multiple methods are combined to predict a mealtime of the user, so that an electronic device can more accurately assess a blood glucose situation of the user.

The invention discloses an insulin dosage fuzzy control method fusing emotion and motion information, and belongs to the technical field of diabetes insulin treatment, and the method comprises the following steps: S1, estimating an emotion state and motion intensity; s2, calculating the current insulin dosage; s3, the structure of a fuzzy controller is determined, input and output fuzzy distribution with the emotional state and the exercise intensity information as input and the insulin dosage adjustment step length as output is defined, and the membership degree of the input relative to different fuzzy subsets is calculated; s4, establishing a fuzzy rule; and S5, performing fuzzy logic reasoning to obtain the output of the fuzzy system, and multiplying the output by the insulin dosage obtained in the step S2 to determine the final insulin dosage. According to the insulin dosage fuzzy control method fusing emotion and motion information, a more personalized and dynamic insulin administration strategy can be realized, a more reasonable insulin dosage can be decided, and the blood glucose management effect of a patient can be improved.

The invention relates to the technical field of intelligent medical monitoring, and discloses a critical patient blood glucose monitoring and risk intervention system based on artificial intelligence. The system comprises a multi-source physiological data integration module, a risk map construction module, an intervention decision generation module and an intervention execution control module. The system integrates and standardizes physiological data from the continuous blood glucose monitor and the multi-parameter monitoring equipment; the physiological parameters are mapped into pathological nodes based on the medical knowledge map, and the activation probability of the pathological nodes is calculated to construct an individualized risk map, so that systematic risk assessment is realized. Further, in combination with individual information of the patient, performing multi-objective optimization on the intervention strategy by applying a simulated annealing algorithm to generate an optimal decision; and analyzing the decision into a control instruction to drive the insulin pump to execute precise intervention. According to the invention, the crossing from passive alarm to active risk prediction and personalized intervention is realized, and the safety and accuracy of blood glucose management of critical patients are improved.

A system implementing a deep learning-based blood glucose simulator for glycemic response takes data from multi-modal information sources and allows users to virtually examine the effects of changes in behavioral parameters on blood glucose. The system predicts blood glucose values based on observation data and iteratively simulates intervention strategies to identify an action for blood glucose management.

The invention provides an intelligent blood glucose management system for gestational diabetes patients. The intelligent blood glucose management system for the gestational diabetes patient comprises a medical terminal, data communication equipment, a cloud platform, a server and a user terminal, wherein the data communication equipment is used for executing data interaction control among the medical terminal, the cloud platform, the server and the user terminal; the cloud platform is used for performing blood glucose risk prediction on the gestational diabetes patient by using the blood glucose parameter information acquired by the medical terminal in combination with a risk prediction model to obtain a risk prediction result; the server is used for storing and managing the blood glucose parameter information and the corresponding risk prediction result; and the user terminal is used for performing storage management on the currently obtained sugar parameter information corresponding to the gestational diabetes patient and the corresponding risk prediction result, and performing data deletion on the sugar parameter information in the historical record and the corresponding risk prediction result.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

Systems and methods for predictive glucose in accordance with embodiments of the invention are illustrated. One embodiment includes glucose management device, including a brain signal recorder, and a controller, including a processor, and a memory, the memory containing a glucose monitoring application configured to direct the processor to record a brain activity signal of a user's brain using the brain signal recorder, and decode the brain activity signal to predict future glucose levels of the patient.

The invention belongs to the field of insulin infusion devices, and discloses an intelligent insulin infusion device for diabetic patients and a blood glucose control method.The device comprises a blood glucose monitoring module, an intelligent insulin infusion module, an AI control center, a user interaction module and a safety monitoring module. The DNN model can accurately predict the short-term blood glucose trend, and the response speed and accuracy of insulin infusion are remarkably improved; a dynamic adjustment algorithm dynamically adjusts the insulin dosage according to individual differences of patients and real-time data, and the risk of complications is reduced; the calculation and response time is reduced through combination of the model and the algorithm, and millisecond-level insulin infusion control is achieved; the system monitors and corrects an insulin infusion strategy in real time, reduces the risk of hypoglycemia and infusion failure, and ensures the safety of a patient. According to the invention, the living quality and the blood glucose management level of the diabetic patient are obviously improved, and meanwhile, the application and development of the intelligent medical technology in chronic disease management are promoted.

The present application relates to a terminal device for blood sugar management during pregnancy and its cloud server, the terminal device collects physiological data and blood sugar data of a target user including the gestation period, the cloud server obtains a plurality of blood sugar data of reference users from a plurality of terminal devices and forms an overall reference data set in a manner associated with gestational age, the cloud server calculates basic statistical indicators for each group in the overall reference data set, combines the specific percentile position of the user's blood sugar data in its own group distribution, judges the current blood sugar state of the user by comparing the user's blood sugar data with the preset healthy blood sugar range, and generates a graded diet suggestion accordingly, the diet suggestion optimizes the diet structure of the target user by selecting food categories with different GI values; the terminal device receives and visually displays personalized diet suggestions matching the blood sugar status of the target user to the target user.

The application discloses a blood sugar management applet with home support function. A data acquisition interaction module is connected with an external blood glucose meter device through a Bluetooth communication protocol to collect blood sugar data of a user in real time; a home collaborative management module realizes safe sharing of blood sugar data of the user among family members, and the family members can check relevant blood sugar data, diet and exercise records through the applet end; and an intelligent analysis and reminding module is based on an LSTM neural network model, performs trend analysis on historical blood sugar data after a risk early warning trigger, generates personalized health reminding information automatically in combination with preset rules, and sends the information to the user and associated family members in a multi-modal form. The application effectively improves the blood sugar management efficiency of patients, reduces the risk of data leakage, and can significantly reduce the fasting blood sugar value and the 2-hour postprandial blood sugar value of patients compared with the prior art, reduces the cost of manual intervention, and has significant clinical application value and social and economic benefits.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

The invention relates to the technical field of intelligent diabetes treatment instruments, in particular to a closed-loop non-invasive insulin detection and precise infusion system which is characterized by comprising a blood glucose monitoring regulator, a non-invasive injector and a closed-loop control mechanism. The closed-loop control mechanism comprises a real-time blood glucose detection module, a temperature detection module, a blood glucose data processing module, a dose decision module, an injection pressure adjusting module, an injection channel control module, an insulin injection module and a closed-loop feedback module; noninvasive and high-sensitivity real-time blood glucose monitoring is achieved, the accuracy and timeliness of insulin administration are improved through trend prediction and individualized dose decision, meanwhile, multi-nozzle array piezoelectric needleless injection is combined with temperature compensation pressure regulation and a closed loop feedback correction mechanism, local tissue burden is effectively reduced, and the insulin administration efficiency is improved. And through multiple safety protection and wireless data transmission, remote monitoring and intelligent management are realized, so that the convenience, accuracy and reliability of blood glucose management of diabetic patients are greatly improved.

The present application relates to a blood sugar management system for pregnancy, comprising terminal devices carried by target users and reference users and a cloud server in data connection with the terminal devices, the cloud server being configured to: acquire physiological data and blood sugar data of the target users from the terminal devices, and calculate characteristic indexes of the target users based on the physiological data and the blood sugar data; acquire a plurality of blood sugar data of the reference users from the terminal devices and form an overall reference data set in a manner associated with gestational weeks, and assign the target users to a predetermined characteristic index value interval in the overall reference data set based on the characteristic indexes, so as to provide personalized health management suggestions for the target users based on factors identified to affect the risk of gestational diabetes mellitus of the target users.

The invention discloses a blood glucose management system used in a hospital, which comprises at least one blood glucose monitoring device comprising a sensor and an emitter, the sensor is used for monitoring blood glucose data of a patient in real time, and the emitter is used for at least emitting blood glucose data information; a plurality of receivers, wherein any one of the plurality of receivers can be used for receiving and transferring the information transmitted by the transmitter; the central server comprises a memory and a communication interface and is used for communicating with external equipment and storing information from the external equipment; and the medical personnel use end equipment is used for communicating with the central server and displaying or checking the blood glucose data information. Due to the fact that any one of the receivers can receive the blood glucose data monitored by the blood glucose monitoring device and upload the blood glucose data to the central server, the activity range of a patient in a hospital is not limited any more, and meanwhile medical staff can conveniently know the blood glucose level of the patient in time and in real time.

A blood glucose management system is disclosed, comprising a user terminal configured to capture an image of food, a processor, and an information providing device configured to provide the processor with blood glucose time-series information of a user prior to ingestion of the food. The processor is configured to execute a step of generating blood glucose trend prediction information of the user after ingestion of the food, based on data related to the food captured by the user terminal and the blood glucose time-series information. The user terminal is configured to display the blood glucose trend prediction information.

Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

1. The name of the product of this design: Interactive Education Board (Daily Blood Glucose Monitoring). 2. Purpose of the product with this appearance design: The interactive education board (daily blood sugar monitoring) product is a wall-mounted acrylic interactive education display board used to educate patients about daily blood sugar monitoring and blood sugar management for diabetes. 3. The design key points of this appearance design product are: the combination of shape, pattern and color. 4. The picture or photo that best illustrates the key points of the design: main view. 5. The design for which protection is sought includes color. 6. The back of this design product is a part that is difficult to see or cannot be seen when in use, so the rear view is omitted. 7. Other situations that require explanation are described in the following figures: (1) The green cursor in the blood glucose self-checking caliper can move along the transparent ruler, and the red button below the transparent ruler can drive the transparent ruler to slide along the track (partial use status can be seen in Figures 1 and 2). (2) Some pages of the flip book can be turned along the ring buckle (partial use status can be seen in Figures 3 and 4).

The invention discloses a personalized blood glucose management method and system for a diabetic patient, and relates to the technical field of personalized management methods, and the method comprises the steps: determining the blood glucose management logic of the diabetic patient according to a plurality of blood glucose control regions and the age of the diabetic patient; the blood glucose management logic is triggered based on the current blood glucose data and the blood glucose variation of the diabetic patient, and the corresponding blood glucose personalized management event is determined according to the blood glucose management level of the diabetic patient and the current event of the diabetic patient, so that the accuracy of the blood glucose personalized management event is ensured. Therefore, the mobile phone worn by the diabetic presents the corresponding blood glucose personalized management content, and records the execution progress of the blood glucose personalized management content; if the execution progress of the personalized blood glucose management content is lower than the preset execution progress threshold value, a blood glucose early warning event built in the mobile phone is triggered, and the diabetic patient is directly informed of an associated early warning contact person, so that the personalized blood glucose management effect of the diabetic patient is further realized.

The invention relates to a blood glucose management system for a gestation period, which comprises terminal equipment carried by a target user and a reference user and a cloud server in data connection with the terminal equipment, and the cloud server is configured to obtain physiological data and blood glucose data including the gestation period of the target user from the terminal equipment, calculating a characteristic index of the target user; acquiring various blood glucose data of a reference user from a plurality of terminal devices, forming an overall reference data set according to a manner associated with gestational weeks, and distributing the target user to a predetermined feature index value interval in the overall reference data set based on the feature index, and providing personalized health management suggestions for the target user based on the identified factors influencing the gestational diabetes risk of the target user.

The present application relates to a kind of based on blood glucose biosensor pregnancy auxiliary system, belong to medical management technical field, especially, it is related to the extended application of biosensor.The system includes: a plurality of user terminals, for obtaining the data information related to user pregnancy, including the blood glucose data obtained based on blood glucose biosensor and the basic information entered;With the communication connection of user terminal server, wherein, the shared database of server construction can be divided into several subgroups based on the preset group division rule, so that each user can be based on its basic information and correspond to one subgroup in the server, the processed blood glucose data obtained by user in current gestation period can be compared with the processed blood glucose data obtained by other users in the same gestation period in corresponding subgroup, to analyze the current blood glucose management of the patient by determining the ranking way, wherein, server can determine the preset group division rule based on the category of basic information.

This invention relates to the field of clinical medical and nursing device technology, specifically to an auxiliary turntable for blood glucose management and insulin dose adjustment in critically ill patients. It includes a base and a recommendation component. A support column is fixedly connected to the top of the base. The recommendation component includes a recommendation disc fitted outside the support column. A judgment component, including a judgment disc fitted outside the support column, is fitted outside the support column and is located on top of the recommendation cover. An identification component, including an identification disc fitted outside the support column, is fitted outside the support column. A base component, including a base disc fitted outside the support column, is located on top of the identification cover. Through the base, support column, and four sets of adjustment components, standardized and visual matching of multiple blood glucose indicators and insulin adjustment recommendations is achieved. Combined with three-color risk label strips, it quickly identifies abnormal blood glucose levels and fluctuation risks, enabling early detection and intervention, and reducing dose adjustment errors due to experience.

The fluid conveying equipment comprises a medicine storage device, a rotating sleeve, a ratchet wheel, a ratchet wheel transmission part and a power assembly, and a piston rod of the medicine storage device is sleeved with the rotating sleeve in a threaded connection mode; the ratchet wheel is mounted on the rotating sleeve in a circumferential limiting manner; the ratchet wheel transmission part is elastically clamped on the tooth surface of the ratchet wheel; the power assembly is in transmission connection with the ratchet transmission part; wherein the power assembly has a first working mode and a second working mode for continuous operation, and in the first working mode, the power assembly drives the ratchet wheel transmission part to perform first movement and is in linkage with the ratchet wheel to rotate by a first angle in the preset direction; in the second working mode, the power assembly drives the ratchet wheel transmission part to conduct second movement and is in linkage with the ratchet wheel to rotate by a second angle in the preset direction. In this way, the structure of the fluid conveying equipment can be simplified, the size is reduced, and the control precision and reliability of the fluid conveying equipment during working are improved.

This invention relates to healthcare information processing technology and discloses an intelligent blood glucose management system for early warning and intervention of gestational diabetes mellitus. The system includes a data acquisition unit, a parameter mapping unit, and a state prediction unit. The data acquisition unit acquires gene polymorphism characteristic parameters and a continuous real-time blood glucose monitoring signal stream. The parameter mapping unit maps the characteristic parameters to the initial state transition matrix of the blood glucose prediction model and determines the process noise covariance matrix. The state prediction unit generates a blood glucose prediction trajectory, calculates the sliding variance of the residual sequence, and triggers covariance adaptive adjustment logic when the sliding variance continuously exceeds a preset threshold. By increasing the diagonal elements of the noise covariance matrix, the blood glucose prediction trajectory is corrected. This invention utilizes a statistically driven adaptive adjustment mechanism to effectively map the nonlinear evolution of the mother's physiological state, eliminate the mismatch between genetic priors and real-time monitoring data, and suppress false positive alarms.

The application relates to a cooking control method, a cooking control device and an automatic cooking equipment, and belongs to the technical field of cooking control. The method is applied to the automatic cooking equipment and comprises the following steps: acquiring real-time blood glucose data collected by a continuous blood glucose monitoring device; based on the real-time blood glucose data, adjusting a cooking parameter of the automatic cooking equipment from a preset cooking parameter to a first cooking parameter; determining a predicted blood glucose change rate and an actual blood glucose change rate of the real-time blood glucose data; in response to an error between the actual blood glucose change rate and the predicted blood glucose change rate corresponding to the same time period exceeding a preset threshold, adjusting the cooking parameter of the automatic cooking equipment from the first cooking parameter to a second cooking parameter based on the error. The above method can automatically adjust the cooking parameter according to the real-time blood glucose data of a user and the blood glucose change rate of the real-time blood glucose data, accurately control the glycemic index of cooked food, adapt to the blood glucose condition of the user, and meet the blood glucose management demand of the user.

Disclosed in the present invention is a blood glucose management system for providing data intercommunication. The system comprises a blood glucose management system used inside a hospital and a blood glucose management system used outside the hospital, wherein a communication connection is established between a central server of the blood glucose management system inside the hospital and a central server of the blood glucose management system outside the hospital, such that missing historical blood glucose data can be complemented each other. When patients are hospitalized and after the patients are discharged from hospital, medical staff, the patients themselves, caregivers or external doctors can obtain complete historical blood glucose records, thereby facilitating the formulation of rapid and effective treatment and rehabilitation plans.

The invention discloses a blood glucose management strategy determination method and device and electronic equipment. The method comprises the following steps: acquiring physical state data of a target object in a target time period; a fine-grained blood glucose management model is adopted to process the physical state data to obtain a target blood glucose management strategy, the fine-grained blood glucose management model is obtained through training of a first blood glucose management strategy set determined by a coarse-grained blood glucose management model, and the precision of the fine-grained blood glucose management model is higher than that of the coarse-grained blood glucose management model; the coarse-grained blood glucose management model is obtained by training historical physical state data of the target object in a first time period, the first blood glucose management strategy set is determined according to historical physical state data of the target object in a second time period, and the end time of the first time period is before the start time of the second time period. The technical problem that a blood glucose management strategy in the related technology cannot perform personalized management strategy recommendation on a single patient is solved.

The invention belongs to the technical field of functional foods and biological medicines, and particularly relates to a pea starch-polyphenol compound as well as a preparation method and application thereof. The raw materials of the pea starch-polyphenol compound comprise the following components in parts by weight: 0.8 to 1.2 parts of pea starch and 0.05 to 0.15 part of polyphenol; the polyphenol comprises at least one of the following components: quercetin, gallic acid and procyanidine. According to the invention, the pea starch is compounded with three polyphenols with different polarities, namely anthocyanin, gallic acid and quercetin, so that the pea starch-quercetin compound shows the most excellent performance: the content of resistant starch can be remarkably increased, and a V-shaped crystal structure is formed; the polypeptide disclosed by the invention shows good blood sugar regulation and intestinal flora regulation functions in vitro and in vivo, can be used for developing functional foods with low glycemic index, assists in blood sugar management of patients with type 2 diabetes, and provides an important basis for developing functional foods and medicines.